The FDA's expedited drug program sparks legal and ethical concerns
The Food and Drug Administration's (FDA) new program, aimed at expediting drug reviews, has sparked concerns and legal questions across the agency. This initiative, championed by FDA Commissioner Marty Makary, has caused anxiety and confusion among staff already grappling with layoffs, buyouts, and leadership changes. The program, which promises approval in as little as one month for medicines supporting U.S. national interests, raises questions about the legal authority of officials to sign off on drugs cleared under it.
Historically, approval decisions have been handled by FDA review scientists and their supervisors, not political appointees. However, drug reviewers report receiving limited information about the program's workings, and some staff working on an anti-obesity pill were instructed to skip regulatory steps to meet aggressive deadlines. Critics argue that the program's fast-track approach lacks scientific precedent and that the FDA cannot conduct thorough reviews in such a short time frame.
The program's popularity at the White House has led to pricing concessions and FDA vouchers for drugmakers. This has raised concerns about political interference in drug reviews, traditionally pegged to objective standards and procedures. The lack of codified rules and regulations for the program has further complicated matters, with agency leaders contacting drugmakers directly about awarding vouchers, creating confusion and quandaries for staff.
The program's legality has been questioned, leading to officials declining to sign off on approvals. The responsibility for final approval carries significant legal risks, as it certifies a drug's safety and effectiveness. If safety issues arise, the agency and staff could face investigations or lawsuits. The program's structure, with approval coming from a committee vote by senior leaders, is seen as a reversal from the traditional review process led by scientists.
Despite concerns, some support the program, citing the commissioner's broad discretion in reorganizing drug reviews. However, the program's short-lived nature is predicted due to its lack of codification, with the potential for the next administration to wipe out current initiatives. The program's expansion, from a pilot of five drugs to 18 vouchers, has put extra pressure on the agency's drug center, which has seen a significant staff turnover in the past year.
The program's future remains uncertain, with critics questioning its scientific and legal soundness. The FDA's approach to drug reviews is under scrutiny, and the agency's ability to balance expedited processes with scientific rigor is a key challenge.
